{'fraction_non_alphanumeric': 0.03413542249580302, 'fraction_numerical': 0.01510912143256855, 'mean_word_length': 5.186851211072664, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Improvement in Nasolabial Folds with a Hyaluronic Acid Filler Using a Cohesive Polydensified Matrix Technology: Results from an 18‐Month Open‐Label Extension Trial

BACKGROUND Repeat treatments of nonpermanent dermal fillers are used in the long‐term treatment of wrinkles and folds and to volumize. OBJECTIVE To determine the safety and effectiveness of a nonanimal‐sourced hyaluronic acid (HA) (which uses a cohesive polydensified matrix (CPM) technology [CPMHA]) for the treatment of nasolabial folds (NLFs) during an 18‐month open‐label extension trial. METHODS AND MATERIALS Ninety‐five of 118 subjects continued with this optional open‐label extension of a split‐face, double‐blind trial. All subjects received CPMHA in both NLFs at 24 weeks after treatment in this study and were assessed at weeks 32, 48, 72, and 96. Touch‐ups were allowed for optimal correction. Safety was assessed according to reported adverse events (AEs) and serum antibody measurement. RESULTS At all four post‐week 24 time points, the severity of the NLFs showed a decrease from baseline on the Wrinkle Severity Rating Scale. The effects persisted in the majority (˜80%) of subjects without repeat treatment for at least one interval of 48 weeks. The study filler was well tolerated, with only one related AE (injection site bruising) reported. Little potential for immunogenic reactions was identified. CONCLUSION This CPMHA is a well‐tolerated and effective treatment for at least 48 weeks in the majority of subjects for the correction of moderate to severe NLFs with repeat injections given over an 18‐month period. This study was sponsored by Merz Pharmaceuticals, LLC. B. Hardas, M. Kaur, S. Grundy, and E. Pappert are employees of Merz. The authors were compensated for their work as investigators.